Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.

Literature DB >> 497087

Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.

F D Juma, H J Rogers, J R Trounce.

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 1979 PMID： 497087 PMCID： PMC1429784 DOI： 10.1111/j.1365-2125.1979.tb01004.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

18 in total

1. Commentary: a physiological approach to hepatic drug clearance.

Authors: G R Wilkinson; D G Shand
Journal: Clin Pharmacol Ther Date: 1975-10 Impact factor: 6.875

2. [ON THE ACTIVATION OF CYCLOPHOSPHAMIDE IN VIVO AND IN VITRO].

Authors: N BROCK; H J HOHORST
Journal: Arzneimittelforschung Date: 1963-12

3. Linear pharmacokinetic models and vanishing exponential terms: implications in pharmacokinetics.

Authors: J G Wagner
Journal: J Pharmacokinet Biopharm Date: 1976-10

4. Changes in hepatic circulation at rest, during and after exercise in young males with infectious hepatitis compared with controls.

Authors: P Lundbergh; T Strandell
Journal: Acta Med Scand Date: 1974-10

5. Phenobarbital effects on cyclophosphamide pharmacokinetics in man.

Authors: J Y Jao; W J Jusko; J L Cohen
Journal: Cancer Res Date: 1972-12 Impact factor: 12.701

6. Urinary metabolites of the antitumor agent cyclophosphamide.

Authors: R F Struck; M C Kirk; L B Mellett; S el Dareer; D L Hill
Journal: Mol Pharmacol Date: 1971-09 Impact factor: 4.436

7. Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs.

Authors: B H Dvorchik; E S Vessell
Journal: Clin Pharmacol Ther Date: 1978-06 Impact factor: 6.875

Review 8. The metabolic fate of cyclophosphamide.

Authors: A R Torkelson; J A LaBudde; J H Weikel
Journal: Drug Metab Rev Date: 1974 Impact factor: 4.518

9. Tissue culture cytotoxicity assay for cyclophosphamide metabolites in rat body fluids.

Authors: F A Weaver; A R Torkelson; W A Zygmunt; H P Browder
Journal: J Pharm Sci Date: 1978-07 Impact factor: 3.534

10. Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography.

Authors: F D Juma; H J Rogers; J R Trounce; I D Bradbrook
Journal: Cancer Chemother Pharmacol Date: 1978 Impact factor: 3.333

38 in total

1. The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.

Authors: L D Lewis; D L Fitzgerald; P Mohan; N Thatcher; P G Harper; H J Rogers
Journal: Br J Clin Pharmacol Date: 1991-01 Impact factor: 4.335

2. Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i.v. bolus administration of thio-TEPA in ovarian cancer patients.

Authors: B Hagen; G Neverdal; R A Walstad; O G Nilsen
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

3. Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.

Authors: Fariba Navid; Sharyn D Baker; M Beth McCarville; Clinton F Stewart; Catherine A Billups; Jianrong Wu; Andrew M Davidoff; Sheri L Spunt; Wayne L Furman; Lisa M McGregor; Shuiying Hu; John C Panetta; David Turner; Demba Fofana; Wilburn E Reddick; Wing Leung; Victor M Santana
Journal: Clin Cancer Res Date: 2012-11-08 Impact factor: 12.531

Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.

1. Commentary: a physiological approach to hepatic drug clearance.

2. [ON THE ACTIVATION OF CYCLOPHOSPHAMIDE IN VIVO AND IN VITRO].

3. Linear pharmacokinetic models and vanishing exponential terms: implications in pharmacokinetics.

4. Changes in hepatic circulation at rest, during and after exercise in young males with infectious hepatitis compared with controls.

5. Phenobarbital effects on cyclophosphamide pharmacokinetics in man.

6. Urinary metabolites of the antitumor agent cyclophosphamide.

7. Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs.

Review 8. The metabolic fate of cyclophosphamide.

9. Tissue culture cytotoxicity assay for cyclophosphamide metabolites in rat body fluids.

10. Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography.

1. The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.

2. Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i.v. bolus administration of thio-TEPA in ovarian cancer patients.

3. Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.

4. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide.

Review 5. Metabolism and pharmacokinetics of oxazaphosphorines.

6. Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.

7. The influence of Fluosol-DA and carbogen breathing on the antitumor effects of cyclophosphamide in vivo.

8. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites.

Review 9. Pharmacokinetics of anticancer drugs in children.

10. Bioavailability of cyclophosphamide from oral formulations.